Effect of SGLT-2 inhibitors on cardiovascular outcomes: review of results of CVD-REAL trial
- Autores: Antsiferov M.B1
-
Afiliações:
- SBHCI "Endocrinological Dispensary" of Moscow Healthcare Department
- Edição: Nº 16 (2017)
- Páginas: 31-37
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289987
- ID: 289987
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article presents a review of the results of real-world international retrospective cohort trial, CVD-REAL, comparing the efficacy of various of sodium-glucose linked transporter-2 (SGLT-2) inhibitors with other antidiabetic drugs in regard to cardiovascular outcomes in patients with type 2 diabetes mellitus (DM2). It is noted that this study supplements the already available results of randomized clinical trials, and indicates the potential of early prescription of SGLT-2 inhibitors for DM2 patients. Studies with a longer follow-up period are required to confirm the long-term and persistent effects of these drugs.
Palavras-chave
Texto integral
Sobre autores
M. Antsiferov
SBHCI "Endocrinological Dispensary" of Moscow Healthcare DepartmentMD, Prof., Chief Physician
Bibliografia
- International Diabetes Federation. IDF Diabetes Atlas. 7th ed., 2015.
- Sarwar N, Gao P., Seshasai S.R. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22.
- Cavender M.A., Steg P.G., Smith S.C., Jr., Eagle K., Ohman E.M., Goto S., Kuder J., Im K., Wilson P.W, Bhatt D.L. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (reach) registry. Circulation. 2015;132:923-31.
- David M. Nathan, for the DCCT/EDIC Research Group*. Diabetes Care. 2014;37:9-16.
- King P, Peacock I., DonnellyR. The UK Prospective Diabetes Study (UKPDS): Clinical and Therapeutic Implications for Type 2 Diabetes. Br. J. Clin. Pharmacol. 1999; 48(5) 643-48.
- FDA. Guidance for Industry. Diabetes Mellitus -Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. December 2008. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulat oryInformation/Guidances/ucm071627.pdf
- Food and Drug Administration Press Release. FDA issues safety alert on Avandia. [Accessed June 2, 2017]; 2007. Available at: https:// www.fda.gov/Drugs/DrugSafety/PostmarketD rugSafetyInformationforPatientsandProviders/ ucm143460.htm
- Green J.B., Bethel M.A.,Armstrong P.W., Buse J.B., Engel S.S., Garg J., et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2015;373(3):232-42.
- Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013;369(14):1317-26.
- White W.B., Cannon C.P, Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013; 369(14):1327-35.
- The ORIGIN Trial Investigators. N. Engl. J. Med. 2012;367:319-28.
- Marc A. Pfeffer, for the ELIXA Investigators. N. Engl. J. Med. 2015 373:2247-257.
- Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., Broedl U.C., Inzucchi S.E., Investigators E-RO. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015;373:2117-28.
- Kosiborod M., on behalf of the CVD-REAL Investigators and Study Team. Lower rates of hospitalization for heart failure in new users of SGLT-2 inhibitors versus other glucose lowering drugs - real world data from six countries and more than 300,000 patients: the CVD-REAL study [presentation]. Presented at: 66th Annual Scientific Session & Expo of the American College of Cardiology; March 17-19, 2017; Washington, DC.
- Kosiborod M., Cavender M.A., Fu A.Z., et al. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study. 2017;135(20).
Arquivos suplementares
